Tesamorelin 10mg

Tesamorelin 10mg is a synthetic growth hormone-releasing hormone (GHRH) analogue supplied as a lyophilised powder for laboratory research use. It is selected within controlled environments for investigation into peptide structure, receptor interaction, and signalling pathways.

Classification: Tesamorelin — a synthetic 44 amino-acid analogue of human growth hormone-releasing hormone (GHRH1–44), with an N-terminal trans-3-hexenoyl modification that increases enzymatic stability.

Within laboratory settings, Tesamorelin is studied for its interaction with growth hormone-releasing hormone (GHRH) receptors and associated endocrine signalling pathways. Research applications focus on receptor binding activity, peptide stability, and hormone pathway modelling under controlled experimental conditions.

This summary describes published preclinical and, where applicable, clinical research. It is not a medical claim and does not describe or endorse any human use of the compound as sold by Peptides UK 4U.

Tesamorelin is studied as a GHRH-receptor agonist that promotes pituitary somatotroph release of endogenous growth hormone. Published research examines its effects on the GH/IGF-1 axis and downstream metabolic parameters in preclinical and clinical settings.

Supplied as a sealed lyophilised vial for in vitro laboratory research only. Handling should be carried out by qualified professionals in a controlled laboratory setting. We do not provide preparation, dosing or usage guidance.

Storage & stability

• Store in a cool, dry environment before reconstitution.
• For extended stability, storage at -20°C is recommended.
• Avoid repeated freeze-thaw cycles after reconstitution.

For in vitro research use only. We do not provide preparation, dosing or usage guidance.

Peptide Type

Synthetic GHRH analogue

Scientific Name

Tesamorelin acetate

Form

Lyophilised powder

Quantity

10mg

Purity

99%+ (subject to batch testing)

Appearance

White lyophilised powder

Solubility

Water soluble

Stability

Maintains integrity under controlled storage conditions

Manufacturing Standard

Produced in controlled laboratory environments

Certificate of Analysis: Available on request from our support team.

• Ferdinandi ES et al., Basic & Clinical Pharmacology & Toxicology 100(1):49–58 (2007) — tesamorelin pharmacology
• Falutz J et al., NEJM 357(23):2359–2370 (2007) — GHRH analogue clinical research

References are provided for educational context. Citation does not imply endorsement of any specific use.